The historical rank and industry rank for Alimera Sciences's Net Margin % or its related term are showing as below:
ALIM'
s Net Margin % Range Over the Past 10 Years
Min: -426.33 Med: -34.31 Max: -7.41
Current: -24.93
ALIM's Net Margin % is ranked worse than 75.2% of 1020
companies
in the Drug Manufacturers industry
Industry Median: 3.765
vs ALIM: -24.93
Alimera Sciences Net Margin % Historical Data
The historical data trend for Alimera Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alimera Sciences's Net Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Alimera Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alimera Sciences's Net Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alimera Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Alimera Sciences's Net Margin % falls into.
Alimera Sciences Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Alimera Sciences's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences (NAS:ALIM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Alimera Sciences Net Margin % Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 